Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases
- PMID:28314621
- PMCID: PMC9087135
- DOI: 10.1016/j.plefa.2017.03.006
Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases
Abstract
Docosahexaenoic acid (DHA), a polyunsaturated fatty acid (PUFA) enriched in phospholipids in the brain and retina, is known to play multi-functional roles in brain health and diseases. While arachidonic acid (AA) is released from membrane phospholipids by cytosolic phospholipase A2 (cPLA2), DHA is linked to action of the Ca2+-independent iPLA2. DHA undergoes enzymatic conversion by 15-lipoxygenase (Alox 15) to form oxylipins including resolvins and neuroprotectins, which are powerful lipid mediators. DHA can also undergo non-enzymatic conversion by reacting with oxygen free radicals (ROS), which cause the production of 4-hydoxyhexenal (4-HHE), an aldehyde derivative which can form adducts with DNA, proteins and lipids. In studies with both animal models and humans, there is evidence that inadequate intake of maternal n-3 PUFA may lead to aberrant development and function of the central nervous system (CNS). What is less certain is whether consumption of n-3 PUFA is important in maintaining brain health throughout one's life span. Evidence mostly from non-human studies suggests that DHA intake above normal nutritional requirements might modify the risk/course of a number of diseases of the brain. This concept has fueled much of the present interest in DHA research, in particular, in attempts to delineate mechanisms whereby DHA may serve as a nutraceutical and confer neuroprotective effects. Current studies have revealed ability for the oxylipins to regulation of cell redox homeostasis through the Nuclear factor (erythroid-derived 2)-like 2/Antioxidant response element (Nrf2/ARE) anti-oxidant pathway, and impact signaling pathways associated with neurotransmitters, and modulation of neuronal functions involving brain-derived neurotropic factor (BDNF). This review is aimed at describing recent studies elaborating these mechanisms with special regard to aging and Alzheimer's disease, autism spectrum disorder, schizophrenia, traumatic brain injury, and stroke.
Keywords: 4-hydoxyhexenal (4-HHE); Alox 15; Antioxidant response element (ARE); Brain development; Brain-derived neurotropic factor (BDNF); Docosahexaenoic acid (DHA); Heme oxygenase-1 (HO-1); IPLA(2); Life spectrum; Neuroinflammation; Neuroprotectin 1 (NPD1); Nuclear factor (erythroid-derived 2)-like 2 (Nrf2); Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB); Oxidative metabolites; Oxylipins; Polyunsaturated fatty acids (PUFA); Resolving; Signaling pathways.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Figures



Similar articles
- Unveiling anti-oxidative and anti-inflammatory effects of docosahexaenoic acid and its lipid peroxidation product on lipopolysaccharide-stimulated BV-2 microglial cells.Yang B, Li R, Michael Greenlief C, Fritsche KL, Gu Z, Cui J, Lee JC, Beversdorf DQ, Sun GY.Yang B, et al.J Neuroinflammation. 2018 Jul 9;15(1):202. doi: 10.1186/s12974-018-1232-3.J Neuroinflammation. 2018.PMID:29986724Free PMC article.
- Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress.Bazan NG.Bazan NG.Brain Pathol. 2005 Apr;15(2):159-66. doi: 10.1111/j.1750-3639.2005.tb00513.x.Brain Pathol. 2005.PMID:15912889Free PMC article.Review.
- Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection.Bazan NG.Bazan NG.Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):205-11. doi: 10.1016/j.plefa.2009.05.024. Epub 2009 Jun 11.Prostaglandins Leukot Essent Fatty Acids. 2009.PMID:19520558Free PMC article.Review.
- Docosahexaenoic acid,22:6n-3: Its roles in the structure and function of the brain.Mallick R, Basak S, Duttaroy AK.Mallick R, et al.Int J Dev Neurosci. 2019 Dec;79:21-31. doi: 10.1016/j.ijdevneu.2019.10.004. Epub 2019 Oct 17.Int J Dev Neurosci. 2019.PMID:31629800Review.
- Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases.Bazan NG, Molina MF, Gordon WC.Bazan NG, et al.Annu Rev Nutr. 2011 Aug 21;31:321-51. doi: 10.1146/annurev.nutr.012809.104635.Annu Rev Nutr. 2011.PMID:21756134Free PMC article.
Cited by
- Docosahexaenoic Acid (DHA) Supplementation Alters Phospholipid Species and Lipid Peroxidation Products in Adult Mouse Brain, Heart, and Plasma.Sun GY, Appenteng MK, Li R, Woo T, Yang B, Qin C, Pan M, Cieślik M, Cui J, Fritsche KL, Gu Z, Will M, Beversdorf D, Adamczyk A, Han X, Greenlief CM.Sun GY, et al.Neuromolecular Med. 2021 Mar;23(1):118-129. doi: 10.1007/s12017-020-08616-0. Epub 2020 Sep 14.Neuromolecular Med. 2021.PMID:32926329Free PMC article.
- The Docosahexanoic Acid: From the Maternal-Fetal Dyad to Early Life Toward Metabolomics.Comitini F, Peila C, Fanos V, Coscia A.Comitini F, et al.Front Pediatr. 2020 Sep 30;8:538. doi: 10.3389/fped.2020.00538. eCollection 2020.Front Pediatr. 2020.PMID:33102402Free PMC article.Review.
- Supplementation of Re-Esterified Docosahexaenoic and Eicosapentaenoic Acids Reduce Inflammatory and Muscle Damage Markers after Exercise in Endurance Athletes: A Randomized, Controlled Crossover Trial.Ramos-Campo DJ, Ávila-Gandía V, López-Román FJ, Miñarro J, Contreras C, Soto-Méndez F, Domingo Pedrol JC, Luque-Rubia AJ.Ramos-Campo DJ, et al.Nutrients. 2020 Mar 9;12(3):719. doi: 10.3390/nu12030719.Nutrients. 2020.PMID:32182747Free PMC article.Clinical Trial.
- Origins of nervous tissue susceptibility to ferroptosis.Snyder J, Wu Z.Snyder J, et al.Cell Insight. 2023 Mar 27;2(3):100091. doi: 10.1016/j.cellin.2023.100091. eCollection 2023 Jun.Cell Insight. 2023.PMID:37398634Free PMC article.Review.
- Molecular basis of unique specificity and regulation of group VIA calcium-independent phospholipase A2 (PNPLA9) and its role in neurodegenerative diseases.Hayashi D, Dennis EA.Hayashi D, et al.Pharmacol Ther. 2023 May;245:108395. doi: 10.1016/j.pharmthera.2023.108395. Epub 2023 Mar 27.Pharmacol Ther. 2023.PMID:36990122Free PMC article.Review.
References
- Sun GY, Horrocks LA, The fatty acid and aldehyde composition of the major phospholipids of mouse brain, Lipids 3 (1968) 79–83. - PubMed
- Sun GY, Horrocks LA, The acyl and alk-1-enyl groups of the major phosphoglycerides from ox brain myelin and mouse brain microsomal, mitochondrial and myelin fractions, Lipids 5 (1970) 1006–1012. - PubMed
- Segawa K, Kurata S, Yanagihashi Y, Brummelkamp TR, Matsuda F, Nagata S, Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure, Science 344 (2014) 1164–1168. - PubMed
- Chen CT, Green JT, Orr SK, Bazinet RP, Regulation of brain polyunsaturated fatty acid uptake and turnover, Prostaglandins Leukot. Ess. Fat. Acids 79 (2008) 85–91. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous